Bayer’s shares crept back above a closely watched technical level on Friday, ending the week at €37.81 with a 4.85% gain. The move pushed the stock just past its 50-day moving average, offering a short-term buy signal for chart-watching investors. Year-to-date, the equity has now rallied roughly 41%, though the 52-week high near €50 remains the longer-term target for bulls.
The modest rebound, however, masks a calendar stuffed with high-stakes events that will determine whether the momentum can hold. Over the next four months, three critical deadlines are set to command the attention of the boardroom and the trading floor alike.
A Supreme Ruling and a Settlement Hearing
The first major date lands at the end of June 2026, when the U.S. Supreme Court is expected to deliver its opinion on whether federal law preempts state-level warning requirements for glyphosate. A favorable ruling for Bayer would remove one of the most potent legal weapons used by plaintiffs in the sprawling Roundup litigation.
Hot on its heels comes the final hearing on the company’s multibillion-dollar class-action settlement, now scheduled for 9 July 2026 in a Missouri court. The hearing was made possible after a federal judge returned the proposed agreement to the St. Louis circuit court, rejecting an attempt by some plaintiffs to block it at the national level. Bayer considers that procedural step a victory, though the ultimate approval remains uncertain.
Washington Turns Up the Heat
Parallel to the court calendar, a political threat is building. The U.S. Trade Representative has launched a formal investigation into German healthcare policies, specifically proposed legislation that would cap spending on innovative drug development. Trade representative Jamieson Greet has warned that Berlin may be shifting too much of its research costs onto American patients. A public hearing is set for September 2026, and written comments are due by 25 June.
Should investors sell immediately? Or is it worth buying Bayer?
The outcome carries significant consequences. If the probe leads to punitive tariffs or trade sanctions, it could disrupt the pricing framework for new medicines across the entire German pharmaceutical sector, not just Bayer.
Operational Bright Spots
Away from the legal and political crosswinds, Bayer continues to make operational progress. The company’s new AI-driven production facility in Leverkusen, SOLIDA-1, recently won an award from the industry body ISPE. Bayer invested roughly €275 million in the plant, which uses artificial intelligence to adjust processes in real time. Management expects the technology to cut production costs by eight to twelve percent, generating an additional gross profit of between €800 million and €1.2 billion over the next five years.
On the personnel front, Kacy Perry will take over the Canadian crop science business from July, overseeing more than 550 employees.
Analyst Views Diverge
Analysts remain split on the near-term outlook. UBS rates Bayer a buy with a target of €52, while Jefferies is more cautious with a “Hold” recommendation and a €40 price objective. The wide gap reflects the uncertainty that surrounds both the legal calendar and the trade probe.
For now, the stock is clinging to its new perch above the 50-day line. If the Supreme Court ruling goes Bayer’s way, the shares could push decisively higher. A negative outcome, however, would put the 200-day moving average at €36.22 back in play as the next support zone. The coming weeks promise to be anything but quiet.
Ad
Bayer Stock: Buy or Sell?! New Bayer Analysis from June 21 delivers the answer:
The latest Bayer figures speak for themselves: Urgent action needed for Bayer investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from June 21.
Bayer: Buy or sell? Read more here...
